Compare Novo Nordisk A/S (NVO) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs RLX Technology Inc — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while RLX Technology Inc trades at $2.03 (market cap $2.52B). The key difference: Novo Nordisk A/S is far larger — about 87.5× RLX Technology Inc's market cap, and RLX Technology Inc pays the higher dividend (4.85%). Which is the better fit depends on your goals.
| NVO | RLX | |
|---|---|---|
Market Cap | $220.53B | $2.52B |
Sector | Health | Technology |
52-Week High | $71.70 | $2.73 |
52-Week Low | $35.29 | $1.79 |
Enterprise Value | $239.49B | $1.15B |
Dividend Yield | 3.63% | 4.85% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
